Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2024 | June 14, 2024 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | May 11, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,159 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 6,820 · Balance 70,159 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2034-06-12 | Direct | 49,933 |
Reported balance
After 2024-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-12 · Grant · Acquired 49,933 · Balance 49,933 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,500 |
Reported balance
Holding disclosure · report date 2024-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Travere Therapeutics, Inc.
Report date May 11, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,919 |
Reported balance
After 2022-05-11 transaction · row 1
1 source rowRow 1 · 2022-05-11 · Sale · Disposed 2,575 · Balance 146,919 F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acer Therapeutics Inc.
Report date November 17, 2023 · Filed November 20, 2023
Section 16 reporting ended · disclosed 2023-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-17 transaction · row 1
1 source rowRow 1 · 2023-11-17 · Disposition to issuer · Disposed 483,741 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra.
F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company.
F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2018 Filed Aug 31, 2018 23:54 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 12,000 | $32.00 | $384,000.00 |
DisclosureSEC source: 0001209191-18-049134 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,883 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 31, 2018 Filed Aug 31, 2018 23:54 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | Exercise / conversionCommon Stock | 12,000 | $8.70 | $104,400.00 |
DisclosureSEC source: 0001209191-18-049134 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:31 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 24,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030054 · doc4.xml · derivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the common stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:31 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 147,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030054 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:31 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 24,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030054 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,883 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 02:13 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | Exercise / conversionCommon Stock Purchase Warrants · Derivative | 278 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-018375 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 278 shares Expires 2018-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 15, 2013, in connection with a private placement of the Issuer's securities, the Reporting Person acquired 556 shares of the Issuer's common stock, par value $0.0001 per share, at a purchase price of $4.50 per share, and Common Stock Purchase Warrants to purchase up to an aggregate of 278 shares of common stock. The aggregate purchase price paid by the Reporting Person in the transaction was $2,502. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 02:13 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | Exercise / conversionCommon Stock | 278 | $6.00 | $1,668.00 |
DisclosureSEC source: 0001209191-18-018375 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 01:37 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009395 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,105 Read SEC document |
| December 26, 2017 Filed Dec 27, 2017 23:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GiftCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067459 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,556 Read SEC document |
| December 21, 2017 Filed Dec 27, 2017 23:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067459 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,556 Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 16:01 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 2,000 | $12.00 | $24,000.00 |
DisclosureSEC source: 0000899243-17-029000 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,905 Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:11 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $15.34 | $0.00 |
DisclosureSEC source: 0001654954-17-009224 · section16.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-10-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on October 4, 2018. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 17:28 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | OtherNonqualified Stock Option (right to buy) · Derivative | 21,000 | Not disclosed Strike: $2.55 | Not disclosed |
DisclosureSEC source: 0001654954-17-008691 · section16.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2025-10-19 F2 · kind: Received in connection with the Merger in exchange for an option to acquire 21,000 shares of common stock of Private Acer. F2 · price: Received in connection with the Merger in exchange for an option to acquire 21,000 shares of common stock of Private Acer. F3 · derivative.exercise_date: Option vests in eight equal quarterly installments beginning on October 19, 2015. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 17:28 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | OtherCommon Stock | 11,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-17-008691 · section16.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,905 F1 · kind: Received in connection with the Issuer's business combination (the "Merger") with what was then known as "Acer Therapeutics Inc." ("Private Acer") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for 11,905 shares of common stock of Private Acer. F1 · price: Received in connection with the Issuer's business combination (the "Merger") with what was then known as "Acer Therapeutics Inc." ("Private Acer") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for 11,905 shares of common stock of Private Acer. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 18:40 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | PurchaseCommon Stock | 5,000 | $17.85 | $89,250.00 |
DisclosureSEC source: 0001209191-17-039792 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,556 Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:14 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 165,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033717 · doc4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal quarterly installments from the date of grant. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:25 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,200 | $21.30 | $68,160.00 |
DisclosureSEC source: 0001209191-16-151969 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,556 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $21.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 21:25 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 5,000 | $21.00 | $105,000.00 |
DisclosureSEC source: 0001209191-16-151969 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,756 Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 21:25 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GiftCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-151969 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,756 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.